Method of treating pancreatic cancer
US-2024415804-A1 · Dec 19, 2024 · US
Medical use of compound from Garcinia esculenta
US9468623B1 · US · B1
| Field | Value |
|---|---|
| Publication number | US-9468623-B1 |
| Application number | US-201615099621-A |
| Country | US |
| Kind code | B1 |
| Filing date | Apr 15, 2016 |
| Priority date | Apr 17, 2015 |
| Publication date | Oct 18, 2016 |
| Grant date | Oct 18, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides compound extracted from Garcinia species and the use of said compound in preventing and treating cancer.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating metastasis of esophageal cancer comprising administering a composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt, prodrug or hydrate thereof. 2. The method of claim 1 , wherein the composition consists essentially of said compound of Formula (I), or said pharmaceutically acceptable salt, prodrug or hydrate thereof. 3. The method of claim 1 , wherein said esophageal cancer is selected from human esophageal carcinoma cell Eca109 and human esophageal cancer cells KYSE150. 4. The method of claim 1 , wherein said metastasis of esophageal cancer is lung metastasis. 5. The method of claim 1 , wherein the composition comprises 1.62 mg of a compound of Formula (I), or a pharmaceutically acceptable salt, prodrug or hydrate thereof per kg of a subject in need thereof. 6. A method of treating esophageal cancer comprising administering a composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt, prodrug or hydrate thereof. 7. The method of claim 6 , wherein the composition consists essentially of said compound of Formula (I), or said pharmaceutically acceptable salt, prodrug or hydrate thereof. 8. The method of claim 6 , wherein said esophageal cancer is selected from human esophageal carcinoma cell Eca109 and human esophageal cancer cells KYSE150. 9. The method of claim 6 , wherein the composition comprises 1.62 mg of a compound of Formula (I), or a pharmaceutically acceptable salt, prodrug or hydrate thereof per kg of a subject in need thereof.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
specific for metastasis · CPC title
Drugs for disorders of the alimentary tract or the digestive system · CPC title
- A61K31/352Primary
condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)} · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9468623B1 cover?
- The present invention provides compound extracted from Garcinia species and the use of said compound in preventing and treating cancer.
- Who is the assignee on this patent?
- Univ Hong Kong Baptist Univ, Univ Shanghai Traditional Chinese Medicine
- What technology area does this patent fall under?
- Primary CPC classification A61K31/352. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 18 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).